Eteplirsen in the treatment of Duchenne muscular dystrophy
Top Cited Papers
Open Access
- 1 February 2017
- journal article
- review article
- Published by Informa UK Limited in Drug Design, Development and Therapy
- Vol. ume11, 533-545
- https://doi.org/10.2147/dddt.s97635
Abstract
Duchenne muscular dystrophy is a fatal neuromuscular disorder affecting around one in 3,500–5,000 male births that is characterized by progressive muscular deterioration. It is inherited in an X-linked recessive fashion and is caused by loss-of-function mutations in the DMD gene coding for dystrophin, a cytoskeletal protein that stabilizes the plasma membrane of muscle fibers. In September 2016, the US Food and Drug Administration granted accelerated approval for eteplirsen (or Exondys 51), a drug that acts to promote dystrophin production by restoring the translational reading frame of DMD through specific skipping of exon 51 in defective gene variants. Eteplirsen is applicable for approximately 14% of patients with DMD mutations. This article extensively reviews and discusses the available information on eteplirsen to date, focusing on pharmacological, efficacy, safety, and tolerability data from preclinical and clinical trials. Issues faced by eteplirsen, particularly those relating to its efficacy, will be identified. Finally, the place of eteplirsen and exon skipping as a general therapeutic strategy in Duchenne muscular dystrophy treatment will be discussed.Keywords
This publication has 64 references indexed in Scilit:
- Long-term outcomes of steroid therapy for Duchenne muscular dystrophy in JapanBrain & Development, 2016
- Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotidesAdvanced Drug Delivery Reviews, 2015
- Magnetic Resonance Imaging and Spectroscopy Assessment of Lower Extremity Skeletal Muscles in Boys with Duchenne Muscular Dystrophy: A Multicenter Cross Sectional StudyPLOS ONE, 2014
- Skipping Multiple Exons of Dystrophin Transcripts Using Cocktail Antisense OligonucleotidesNucleic Acid Therapeutics, 2014
- Antisense Therapy in NeurologyJournal of Personalized Medicine, 2013
- Development of the Performance of the Upper Limb module for Duchenne muscular dystrophyDevelopmental Medicine and Child Neurology, 2013
- Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutationsHuman Mutation, 2009
- Update on the management of Duchenne muscular dystrophyArchives of Disease in Childhood, 2008
- Dystrophin, its interactions with other proteins, and implications for muscular dystrophyBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2007
- A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actinThe Journal of cell biology, 1993